Chinese herbs in treatment of influenza: A multi-centre, randomized, double-blind, placebo-controlled trial

L. Wang, R. M. Zhang, G. Y. Liu, B. L. Wei, Y. Wang, H. Y. Cai, F. S. Li, Y. L. Xu, S. P. Zheng, G. Wang (Chengdu, , Taiyuan, Changchun, Urumqi, Shenyang, China)

Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections
Session: New aspects of treatment of lower respiratory tract infections
Session type: Oral Presentation
Number: 5579

Congress or journal article abstractSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Wang, R. M. Zhang, G. Y. Liu, B. L. Wei, Y. Wang, H. Y. Cai, F. S. Li, Y. L. Xu, S. P. Zheng, G. Wang (Chengdu, , Taiyuan, Changchun, Urumqi, Shenyang, China). Chinese herbs in treatment of influenza: A multi-centre, randomized, double-blind, placebo-controlled trial. Eur Respir J 2010; 36: Suppl. 54, 5579

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effectiveness of influenza vaccination in asthmatic children: randomised, double-blind, placebo-controlled trial
Source: Eur Respir J 2002; 20: Suppl. 38, 146s
Year: 2002

Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD
Source: Annual Congress 2009 - Healthcare and treatment of COPD
Year: 2009


Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial
Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021
Year: 2021



PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017



Chinese herbs in treatment of postinfectious cough: A multi-centre, randomized, double-blind, placebo-controlled trial
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013

Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)
Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021
Year: 2022



Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



Randomized double-blind placebo-controlled trial of azithromycin in lung transplantation: first results
Source: Annual Congress 2008 - New insights and treatment options for bronchiolitis obliterans syndrome after lung transplantation
Year: 2008


Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial
Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021
Year: 2022



Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010


Efficacy and safety of a novel nicotine mouth spray in smoking cessation: A randomized, placebo-controlled, double blind, multicenter study with 52-week follow up
Source: Annual Congress 2011 - Smoking cessation science
Year: 2011

Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Towards controlling severe asthma
Year: 2007


Effect of reflexology, homeopathy, and traditional medical treatment in asthma: A randomised, controlled, parallel-group trial
Source: Annual Congress 2010 - Questionnaires use and psychological aspects in asthma
Year: 2010


Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial
Source: Eur Respir J, 58 (4) 2002819; 10.1183/13993003.02819-2020
Year: 2021



Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011

A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 498s
Year: 2006

A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018